Allergan Aesthetics, a division of AbbVie (NYSE: ABBV), has launched Allē Payment Plans, powered by Cherry, to offer consumers the ability to pay for aesthetic treatments and products, including BOTOX® Cosmetic (onabotulinumtoxinA) and the JUVÉDERM® Collection of Fillers, over time.…
TVM Capital Healthcare Announces $35 Million Investment in Boston Oncology Arabia TVM Capital Healthcare, an international healthcare expansion and growth capital firm, has announced a $35 million investment in Boston Oncology Arabia, a bio-generic drugs manufacturing company based in the…
Audrey Duval Derveloy Appointed Global Head of Corporate Affairs at Sanofi Audrey Duval Derveloy, a seasoned leader in the healthcare industry and current President of Sanofi France, has been appointed Executive Vice President and Global Head of Corporate Affairs at…
AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has received approval from the European Union (EU) for treating adult patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer that harbors one or more PIK3CA, AKT1, or PTEN…
Lilly’s Commitment to Safe Use of Mounjaro® and Zepbound® Lilly is dedicated to improving lives for people with diabetes and obesity through innovative medications like Mounjaro® and Zepbound®. Guided by our founder’s principle, “If it bears a red Lilly, it’s…
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global leader in oncology, has unveiled new findings from the SEQUOIA study of BRUKINSA® (zanubrutinib) today at EHA2024 in Madrid, Spain. The presentation highlighted results from arm D, exploring BRUKINSA in…
Enveda Biosciences Secures $55M to Advance AI-Driven Drug Development Enveda Biosciences, known for its pioneering use of AI in drug discovery, has announced a $55 million financing round. This round, which includes investments from new backers like Premji Invest, Lingotto…
WHO remains concerned about the escalating health crisis in the occupied Palestinian territory, including the West Bank, where attacks on health infrastructure and increased restrictions on movement are obstructing access to health care. A spike in violence in the West…
WHO Releases Latest Report on Antibacterial Development The World Health Organization (WHO) has published its most recent assessment of antibacterial agents, encompassing antibiotics in various stages of clinical and preclinical development worldwide. The report reveals a notable increase in the…
A pivotal debate titled “How to Defeat Aging,” hosted by Open Longevity at the Foresight Institute on May 27, 2024, concluded with an unexpected outcome that shed light on the evolving landscape of rejuvenation biotechnology. The event featured Dr. Aubrey…
Sibylla Biotech and The University of Texas MD Anderson Cancer Center have announced a strategic collaboration to discover and develop novel small-molecule cancer therapies called Folding Interfering Degraders (FIDs). These therapies disrupt the proper folding of target proteins, leading to…
The European Commission has approved Alecensa® (alectinib) monotherapy as an adjuvant treatment for adult patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who are at high risk of recurrence (Stage IB [≥4 cm]–IIIA NSCLC [7ᵗʰ edition UICC/AJCC])…